Systems and methods for delivery of a therapeutic agent

Patent metadata

Field	Value
Publication number	US-10022529-B2
Application number	US-201615358187-A
Country	US
Kind code	B2
Filing date	Nov 22, 2016
Priority date	Jul 22, 2005
Publication date	Jul 17, 2018
Grant date	Jul 17, 2018

Abstract

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

First claim

What is claimed is:

1. A nerve modification device for altering nerve function in a bronchial airway of a patient, the nerve modification device comprising:
a main catheter body configured to extend though a trachea into the bronchial airway; and
at least one energy applicator having at least one energy emitter configured to emit energy laterally relative to the main catheter body,
wherein the nerve modification device is adapted to deliver energy from the at least one energy emitter to produce an energy field concentrated in a target region in the wall of the bronchial airway in a first lateral direction from the main catheter body to alter nerve cells within the target region.

2. The nerve modification device of claim 1 , wherein the energy is at least one of x-ray energy, radiofrequency energy, DC current, AC current, microwave energy, and ultrasound energy.

3. The nerve modification device of claim 1 , wherein the at least one energy emitter comprises at least one electrode.

4. The nerve modification device of claim 3 , wherein the energy is RF energy.

5. The nerve modification device of claim 1 , wherein the at least one energy emitter comprises at least one ultrasound transducer.

6. The nerve modification device of claim 5 , wherein the energy is ultrasound energy.

7. The nerve modification device of claim 1 , wherein the energy applicator is configured to be positionable in contact with a first portion of a circumference of the airway wall.

8. A system for altering nerve function in a bronchial airway of a patient, the system comprising:
an intraluminal catheter configured to be positioned within a bronchial airway of a patient, the intraluminal catheter including:
a main catheter body, and
a first energy emitter configured to emit energy laterally relative to the main catheter body; and

an energy generator operably coupled to the first energy emitter and configured to activate the first energy emitter, thereby causing an energy field to be generated in a target region in the airway wall to alter nerve cells within the target region.

9. The system of claim 8 , wherein the main catheter body is configured to be positionable such that the first energy emitter is in contact with a first portion of a circumference of the airway wall.

10. The system of claim 8 , further comprising:
a second energy emitter operably coupled to the energy generator, the second energy emitter being configured to be positioned outside of the airway and remote from the target region, the target region being positioned between the first and second energy emitters such that activation of the first and second energy emitters by the energy generator produces the energy field between the first and second emitters and within the target region.

11. The system of claim 10 , wherein a placement of the first and second energy emitters relative to each other controls the size and/or intensity of the energy field.

12. The system of claim 8 , the system further comprising:
a second energy emitter operably coupled to the energy generator, such that an arrangement of the first and second energy emitters causes the energy field produced therefrom to be concentrated in a lateral direction from the main catheter body.

13. The system of claim 8 , a second energy emitter operably coupled to the energy generator, such that an arrangement of the first and second energy emitters causes the energy field produced therefrom to comprise a uniform energy field about the main catheter body.

14. The system of claim 8 , wherein the energy is at least one of x-ray energy, radiofrequency energy, DC current, AC current, microwave energy, and ultrasound energy.

15. The system of claim 8 , wherein the first energy emitter comprises an electrode.

16. The system of claim 15 , wherein the energy is RF energy.

17. The system of claim 8 , wherein the first energy emitter comprises an ultrasound transducer.

18. A method, comprising:
causing a nerve modification device to be manufactured and made available to a user, the nerve modification device including a main catheter body and at least one energy applicator having at least one energy emitter; and
providing instructions to the user for use of the nerve modification device, the instructions recorded on a tangible or non-transitory computer-readable medium and including:
positioning the nerve modification device at a treatment site in a bronchial airway of a patient; and
causing the nerve modification device to deliver energy from the at least one energy emitter to produce an energy field concentrated in a target region in the wall of the bronchial airway in a first lateral direction from the main catheter body to alter nerve cells within the target region.

19. The method of claim 18 , wherein causing the nerve modification device to deliver energy from the at least one energy emitter comprises causing the nerve modification device to deliver a pulse of radio frequency energy.

20. The method of claim 18 , wherein causing the nerve modification device to deliver energy from the at least one energy emitter comprises causing the nerve modification device to deliver one of x-ray energy, radiofrequency energy, DC current, AC current, microwave energy, and ultrasound energy.

Assignees

• Foundry Llc

Inventors

• Deem Mark E
• Gifford Iii Hanson S

Classifications

• A61K9/0021 Primary

  Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/06

  Antimigraine agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P21/02

  Muscle relaxants, e.g. for tetanus or cramps · CPC title